Hutchmed (China) Limited — RNS

Regulatory news across HCM, HCM

Date	TIDM	Time	Date	TIDM	TitleTitle (filtered)	Company	Source
14/11/22	HCM	07:00:06	14 Nov 2022	Positive Topline Phase 3 Result in Fruquintinib	HCM	Positive Topline Phase 3 Result in Fruquintinib	Hutchmed (China) Limited	RNS
27/10/22	HCM	12:30:01	27 Oct 2022	HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib	HCM	HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib	Hutchmed (China) Limited	RNS
21/10/22	HCM	09:30:00	21 Oct 2022	Vesting of awards under the LTIP	HCM	Vesting of awards under the LTIP	Hutchmed (China) Limited	RNS
10/10/22	HCM	09:30:06	10 Oct 2022	Phase II/III Trial of Sovleplenib for in China	HCM	Phase II/III Trial of Sovleplenib for in China	Hutchmed (China) Limited	RNS
30/09/22	HCM	09:30:05	30 Sept 2022	Total Voting Rights	HCM	Total Voting Rights	Hutchmed (China) Limited	RNS
14/09/22	HCM	11:00:05	14 Sept 2022	Share Option Scheme and Long Term Incentive Plan	HCM	Share Option Scheme and Long Term Incentive Plan	Hutchmed (China) Limited	RNS
08/09/22	HCM	07:00:06	8 Sept 2022	FRESCO-2 Colorectal Cancer MRCT Data Highlights	HCM	FRESCO-2 Colorectal Cancer MRCT Data Highlights	Hutchmed (China) Limited	RNS
23/08/22	HCM	10:00:04	23 Aug 2022	Holding(s) in Company	HCM	Holding(s) in Company	Hutchmed (China) Limited	RNS
23/08/22	HCM	09:30:06	23 Aug 2022	HUTCHMED To Present FRESCO-2 Data at ESMO 2022	HCM	HUTCHMED To Present FRESCO-2 Data at ESMO 2022	Hutchmed (China) Limited	RNS
09/08/22	HCM	09:30:06	9 Aug 2022	First Participant in Phase I Trial of IMG-004	HCM	First Participant in Phase I Trial of IMG-004	Hutchmed (China) Limited	RNS
08/08/22	HCM	09:30:05	8 Aug 2022	Preliminary results from SAVANNAH Phase 2 Trial	HCM	Preliminary results from SAVANNAH Phase 2 Trial	Hutchmed (China) Limited	RNS
08/08/22	HCM	07:00:06	8 Aug 2022	FRESCO-2 Study Has Met Primary Endpoint	HCM	FRESCO-2 Study Has Met Primary Endpoint	Hutchmed (China) Limited	RNS
01/08/22	HCM	12:04:30	1 Aug 2022	Interim Results and Business Updates	HCM	Interim Results and Business Updates	Hutchmed (China) Limited	RNS
01/08/22	HCM	07:00:12	1 Aug 2022	HUTCHMED Initiates Bridging Study of Tazemetostat	HCM	HUTCHMED Initiates Bridging Study of Tazemetostat	Hutchmed (China) Limited	RNS
15/07/22	HCM	09:30:01	15 Jul 2022	HUTCHMED Initiates Phase I Trial of HMPL-A83	HCM	HUTCHMED Initiates Phase I Trial of HMPL-A83	Hutchmed (China) Limited	RNS
13/07/22	HCM	07:00:07	13 Jul 2022	Results of SAVANNAH Global Phase II Trial at WCLC	HCM	Results of SAVANNAH Global Phase II Trial at WCLC	Hutchmed (China) Limited	RNS
06/07/22	HCM	07:00:12	6 Jul 2022	First Participants in Phase I Trial of IMG-007	HCM	First Participants in Phase I Trial of IMG-007	Hutchmed (China) Limited	RNS
30/06/22	HCM	09:30:06	30 Jun 2022	Total Voting Rights	HCM	Total Voting Rights	Hutchmed (China) Limited	RNS
29/06/22	HCM	09:30:06	29 Jun 2022	Blocklisting Six Monthly Return	HCM	Blocklisting Six Monthly Return	Hutchmed (China) Limited	RNS
27/06/22	HCM	09:30:01	27 Jun 2022	HUTCHMED to Announce 2022 Half-Year Results	HCM	HUTCHMED to Announce 2022 Half-Year Results	Hutchmed (China) Limited	RNS
01/06/22	HCM	09:30:01	1 Jun 2022	TAZVERIK® Approved in Hainan Pilot Zone	HCM	TAZVERIK® Approved in Hainan Pilot Zone	Hutchmed (China) Limited	RNS
24/05/22	HCM	11:00:01	24 May 2022	LTIP and Share Options	HCM	LTIP and Share Options	Hutchmed (China) Limited	RNS
16/05/22	HCM	12:00:07	16 May 2022	Appointment of Non–Executive Director	HCM	Appointment of Non–Executive Director	Hutchmed (China) Limited	RNS
03/05/22	HCM	07:00:13	3 May 2022	HUTCHMED Receives CRL from the US FDA	HCM	HUTCHMED Receives CRL from the US FDA	Hutchmed (China) Limited	RNS
27/04/22	HCM	14:30:07	27 Apr 2022	Annual General Meeting Poll Results	HCM	Annual General Meeting Poll Results	Hutchmed (China) Limited	RNS
21/04/22	HCM	09:30:01	21 Apr 2022	Vesting of awards under Long Term Incentive Plan	HCM	Vesting of awards under Long Term Incentive Plan	Hutchmed (China) Limited	RNS
31/03/22	HCM	07:00:09	31 Mar 2022	Update on Status under HFCAA	HCM	Update on Status under HFCAA	Hutchmed (China) Limited	RNS
23/03/22	HCM	08:30:02	23 Mar 2022	2021 Annual Report and Notice of AGM	HCM	2021 Annual Report and Notice of AGM	Hutchmed (China) Limited	RNS
11/03/22	HCM	09:00:01	11 Mar 2022	Update on Status under HFCAA	HCM	Update on Status under HFCAA	Hutchmed (China) Limited	RNS
09/03/22	HCM	08:30:01	9 Mar 2022	Vesting of awards under Long Term Incentive Plan	HCM	Vesting of awards under Long Term Incentive Plan	Hutchmed (China) Limited	RNS
07/03/22	HCM	07:00:11	7 Mar 2022	HUTCHMED Receives $15m Milestone from AstraZeneca	HCM	HUTCHMED Receives $15m Milestone from AstraZeneca	Hutchmed (China) Limited	RNS
03/03/22	HCM	15:30:07	3 Mar 2022	Publication of Form 20-F	HCM	Publication of Form 20-F	Hutchmed (China) Limited	RNS
03/03/22	HCM	12:30:06	3 Mar 2022	Retirement of CEO and appointment of new CEO	HCM	Retirement of CEO and appointment of new CEO	Hutchmed (China) Limited	RNS
03/03/22	HCM	12:00:06	3 Mar 2022	Full Year Results and Business Updates	HCM	Full Year Results and Business Updates	Hutchmed (China) Limited	RNS
01/03/22	HCM	08:30:01	1 Mar 2022	Approval to Commercialize ELUNATE® in Macau	HCM	Approval to Commercialize ELUNATE® in Macau	Hutchmed (China) Limited	RNS
07/02/22	HCM	08:30:02	7 Feb 2022	HUTCHMED to Announce 2021 Final Results	HCM	HUTCHMED to Announce 2021 Final Results	Hutchmed (China) Limited	RNS
04/02/22	HCM	09:30:08	4 Feb 2022	Phase Ib/II Combination Study of HMPL-453	HCM	Phase Ib/II Combination Study of HMPL-453	Hutchmed (China) Limited	RNS
20/01/22	HCM	07:00:09	20 Jan 2022	HUTCHMED Initiates Phase I Trial of HMPL-653	HCM	HUTCHMED Initiates Phase I Trial of HMPL-653	Hutchmed (China) Limited	RNS
19/01/22	HCM	07:00:08	19 Jan 2022	HUTCHMED Data at ASCO GI Cancers Symposium	HCM	HUTCHMED Data at ASCO GI Cancers Symposium	Hutchmed (China) Limited	RNS
17/01/22	HCM	09:00:02	17 Jan 2022	Holding(s) in Company	HCM	Holding(s) in Company	Hutchmed (China) Limited	RNS
12/01/22	HCM	11:00:01	12 Jan 2022	Breakthrough Therapy Designation for HMPL-523	HCM	Breakthrough Therapy Designation for HMPL-523	Hutchmed (China) Limited	RNS
10/01/22	HCM	07:00:10	10 Jan 2022	HUTCHMED Initiates Phase I Study of HMPL-760	HCM	HUTCHMED Initiates Phase I Study of HMPL-760	Hutchmed (China) Limited	RNS
31/12/21	HCM	07:00:04	31 Dec 2021	Blocklisting Six Monthly Return	HCM	Blocklisting Six Monthly Return	Hutchmed (China) Limited	RNS
31/12/21	HCM	07:00:03	31 Dec 2021	Total Voting Rights	HCM	Total Voting Rights	Hutchmed (China) Limited	RNS
20/12/21	HCM	07:00:08	20 Dec 2021	HUTCHMED Included in FTSE Russell Indexes	HCM	HUTCHMED Included in FTSE Russell Indexes	Hutchmed (China) Limited	RNS
15/12/21	HCM	09:45:01	15 Dec 2021	Grant of Share Options and Awards under LTIP	HCM	Grant of Share Options and Awards under LTIP	Hutchmed (China) Limited	RNS
14/12/21	HCM	07:00:11	14 Dec 2021	HMPL-523 Clinical Data Presented at ASH	HCM	HMPL-523 Clinical Data Presented at ASH	Hutchmed (China) Limited	RNS
10/12/21	HCM	10:00:01	10 Dec 2021	HUTCHMED Presents Data at ESMO Immuno-Oncology ‘21	HCM	HUTCHMED Presents Data at ESMO Immuno-Oncology ‘21	Hutchmed (China) Limited	RNS
06/12/21	HCM	07:00:09	6 Dec 2021	HUTCHMED Completes Planned Enrollment of FRESCO-2	HCM	HUTCHMED Completes Planned Enrollment of FRESCO-2	Hutchmed (China) Limited	RNS
03/12/21	HCM	07:00:04	3 Dec 2021	Updated NRDL to include ELUNATE and SULANDA	HCM	Updated NRDL to include ELUNATE and SULANDA	Hutchmed (China) Limited	RNS

Showing 201–250 of 297 announcements